PI Industries Moat Analysis: Score & Risks
PI Industries Ltd.
A first-pass moat teardown of PI Industries Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow → wide read — primary edge in Cost Advantage. Provisional, single-pass evidence.
PI Industries Ltd. scores 5.54 on MoatSCORE 6.0 — a narrow → wide moat in Chemicals. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“As a result of these efforts, we have significantly reduced energy consumption, improved resource efficiency, and strengthened cost competitiveness—demonstrating how innovation can power operational excellence at scale.”
“Non conflicting business model … well respected by Global Innovators as Partners”
“During FY 2024-25, the Company enhanced its integrated platform capabilities spanning R&D, kilo/pilot plants and commercial scale manufacturing.”
“In U.S., we are setting up a distribution network for the entire Midwest and some of the world's largest farmers from Brazil and Mexico, they are basically right now testing our products.”
“While the ETR for the quarter has risen due to higher non-SEZ sales, on a full year basis, the ETR for FY26 remains at 22%. We expect FY27 and thereafter ETR to inch upto 24%.”
“The consolidated revenue of Plant Health Care Limited stood at Rs. 537 million with net loss of Rs. 326 million for the period August 20, 2024 to March 31, 2025.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion